Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,365 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03316222 | Study of GNS561 in Patients With Liver Cancer | terminated | Phase 1 / Phase 2 | 50 | Genoscience PharmaINDUSTRY | 3 | May 2, 2022 | clinicaltrials |
| NCT01587040 | Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen | completed | Phase 1 / Phase 2 | 61 | SanofiINDUSTRY | 4 | Apr 19, 2022 | clinicaltrials |
| NCT03799731 |
| Study for Evaluation of Murlentamab (GM102) Anti-tumoral Activity in Colorectal Cancers |
| completed |
| Phase 2 |
| 65 |
| GamaMabs PharmaINDUSTRY |
| 2 |
| Apr 14, 2022 |
| clinicaltrials |
| NCT03713320 | SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides(SOLAR) | terminated | Phase 2 | 37 | miRagen Therapeutics, Inc.INDUSTRY | 8 | Apr 8, 2022 | clinicaltrials |
| NCT04614493 | Innovative SonoCloud-9 Device for Blood Brain Barrier Opening in First Line Temozolomide Glioblastoma Patients.(SonoFIRST) | unknown | Phase 2 | 66 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Mar 29, 2022 | clinicaltrials |
| NCT02978716 | Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) | terminated | Phase 2 | 102 | G1 Therapeutics, Inc.INDUSTRY | 8 | Mar 23, 2022 | clinicaltrials |
| NCT04648319 | A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma | terminated | Phase 2 | 1 | American University of Beirut Medical CenterOTHER | 3 | Feb 23, 2022 | clinicaltrials |
| NCT04552847 | Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors | completed | Phase 2 / Phase 3 | 85 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02460224 | Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. | completed | Phase 1 / Phase 2 | 490 | Novartis PharmaceuticalsINDUSTRY | 12 | Feb 10, 2022 | clinicaltrials |
| NCT02077166 | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 138 | Pharmacyclics LLC.INDUSTRY | 4 | Feb 4, 2022 | clinicaltrials |
| NCT01518517 | GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia(GRASPIVOTALL) | completed | Phase 2 / Phase 3 | 85 | ERYtech PharmaINDUSTRY | 2 | Feb 2, 2022 | clinicaltrials |
| NCT00603954 | Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings | completed | Phase 2 | 107 | University of LiegeOTHER | 2 | Jan 26, 2022 | clinicaltrials |
| NCT03637491 | A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors | terminated | Phase 1 / Phase 2 | 36 | PfizerINDUSTRY | 3 | Jan 26, 2022 | clinicaltrials |
| NCT03647488 | Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer | completed | Phase 2 | 18 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 24, 2022 | clinicaltrials |
| NCT02038946 | Study of Nivolumab in Subjects With Relapsed or Refractory Follicular Lymphoma (FL) (CheckMate 140) | completed | Phase 2 | 116 | Bristol-Myers SquibbINDUSTRY | 12 | Jan 4, 2022 | clinicaltrials |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 195 | Seagen Inc.INDUSTRY | 5 | Dec 29, 2021 | clinicaltrials |
| NCT02686346 | Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE(BV-ICE) | completed | Phase 1 / Phase 2 | 53 | The Lymphoma Academic Research OrganisationOTHER | 2 | Dec 7, 2021 | clinicaltrials |
| NCT02366195 | Single-arm Trial to Evaluate the Role of the Immune Response to Talimogene Laherparepvec in Unresected Melanoma(TVEC-325) | completed | Phase 2 | 112 | AmgenINDUSTRY | 13 | Nov 30, 2021 | clinicaltrials |
| NCT02725268 | A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer | completed | Phase 2 | 241 | Millennium Pharmaceuticals, Inc.INDUSTRY | 10 | Nov 24, 2021 | clinicaltrials |
| NCT02078960 | A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study) | terminated | Phase 1 / Phase 2 | 10 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 4 | Nov 9, 2021 | clinicaltrials |
| NCT02052960 | CetuGEX™ in Comparison to Cetuximab for the Treatment of Patients With Head and Neck Cancer(RESGEX) | completed | Phase 2 | 240 | Glycotope GmbHINDUSTRY | 7 | Nov 2, 2021 | clinicaltrials |
| NCT03736967 | Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis | terminated | Phase 2 | 206 | Regeneron PharmaceuticalsINDUSTRY | 7 | Nov 1, 2021 | clinicaltrials |
| NCT00865969 | Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma(PTCL) | completed | Phase 2 | 129 | Spectrum Pharmaceuticals, IncINDUSTRY | 17 | Oct 29, 2021 | clinicaltrials |
| NCT01750918 | BRAF/MEK/EGFR Inhibitor Combination Study in Colorectal Cancer (CRC) | completed | Phase 1 / Phase 2 | 166 | Novartis PharmaceuticalsINDUSTRY | 8 | Oct 29, 2021 | clinicaltrials |
| NCT03890744 | ModraDoc006/r in Patients With Breast Cancer | completed | Phase 2 | 12 | Modra PharmaceuticalsINDUSTRY | 3 | Oct 19, 2021 | clinicaltrials |
| NCT02038933 | Study of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139) | completed | Phase 2 | 121 | Bristol-Myers SquibbINDUSTRY | 12 | Oct 14, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT02614833 | IMP321 (Eftilagimod Alpha) as Adjunctive to a Standard Chemotherapy Paclitaxel Metastatic Breast Carcinoma | completed | Phase 2 | 242 | Immutep S.A.S.INDUSTRY | 7 | Oct 5, 2021 | clinicaltrials |
| NCT04882163 | Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma | withdrawn | Phase 1 / Phase 2 | 0 | CelgeneINDUSTRY | 8 | Oct 5, 2021 | clinicaltrials |
| NCT03887156 | Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft(Predictor2) | unknown | Phase 2 / Phase 3 | 227 | Assistance Publique - Hôpitaux de ParisOTHER | 3 | Sep 28, 2021 | clinicaltrials |
| NCT04114825 | Study of RV001V in Biochemical Failure Following Curatively Intended Therapy For Localized Prostate Cancer(BRaVac) | active not recruiting | Phase 2 | 180 | RhoVac APSINDUSTRY | 7 | Sep 28, 2021 | clinicaltrials |
| NCT00880009 | Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer | terminated | Phase 2 | 16 | PfizerINDUSTRY | 7 | Sep 27, 2021 | clinicaltrials |
| NCT02808247 | Ph II Nintedanib vs. Ifosfamide in Soft Tissue Sarcoma(ANITA) | terminated | Phase 2 | 80 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | Sep 20, 2021 | clinicaltrials |
| NCT01913652 | Ph II Cabazitaxel DD Liposarcoma | completed | Phase 2 | 42 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 14, 2021 | clinicaltrials |
| NCT01045382 | MSC and HSC Coinfusion in Mismatched Minitransplants | terminated | Phase 2 | 39 | University of LiegeOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT02984683 | Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer | terminated | Phase 2 | 23 | SanofiINDUSTRY | 5 | Sep 8, 2021 | clinicaltrials |
| NCT03192059 | Study of Pembrolizumab, Radiation and Immune Modulatory Cocktail in Cervical/Uterine Cancer(PRIMMO) | completed | Phase 2 | 43 | University Hospital, GhentOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT00425555 | Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma | completed | Phase 2 | 139 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 20, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT03052751 | Study to Test the Safety, Tolerability and Efficacy of UCB7665 in Subjects With Moderate to Severe Myasthenia Gravis | completed | Phase 2 | 43 | UCB Biopharma S.P.R.L.INDUSTRY | 7 | Aug 3, 2021 | clinicaltrials |
| NCT00742027 | Phase II Study of Oral Panobinostat in Adult Participants With Relapsed/Refractory Classical Hodgkin's Lymphoma | completed | Phase 2 | 129 | Novartis PharmaceuticalsINDUSTRY | 13 | Jul 28, 2021 | clinicaltrials |
| NCT01553786 | Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) | completed | Phase 2 | 80 | The Lymphoma Academic Research OrganisationOTHER | 2 | Jul 26, 2021 | clinicaltrials |
| NCT00451035 | Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase | terminated | Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 2 | Jul 15, 2021 | clinicaltrials |
| NCT02216578 | Ph II CABOGIST in GIST | completed | Phase 2 | 51 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Jul 15, 2021 | clinicaltrials |
| NCT00806156 | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer | completed | Phase 2 | 178 | Nektar TherapeuticsINDUSTRY | 3 | Jul 12, 2021 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials